Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo treatments for alopecia areata: microneedling plus lactic acid, vitamin d, or steroid

NCT ID NCT06327581

Disease control Sponsor: Zagazig University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether microneedling combined with one of three substances—lactic acid, vitamin D3, or a steroid (triamcinolone acetonide)—can help regrow hair in people with patchy alopecia areata. Eighty-eight participants will receive one of the four treatments (including a saline control) over several sessions. The goal is to see which combination works best for hair regrowth.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
lactic acid, vitamin D3, triamcinolone acetonide
What this could lead to
If successful, this could point toward a more effective, minimally invasive treatment option for patchy alopecia areata that combines microneedling with a topical agent.
What could go wrong
This is a small, early-phase comparative study (88 participants) with no blinding or placebo control, so results may not be conclusive. Side effects like skin irritation or atrophy are possible with the treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 88 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2023

Expected to finish

Dec 2026

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * · Age ≥ 16 years old with localized patchy AA (up to 6 cm in diameter). * Patients of both sexes * Willing to participate in the study and to sign an informed consent. Exclusion Criteria: * · Patients who received systemic or topical treatment for AA in the last 3 months prior to the start of the study * Patients with Alopecia totalis, universalis, ophiasis, or sisaipho * Pregnant or lactating females * Patients who had bleeding or coagulation disorders * Immunocompromised patients * Patients with known history of hypersensitivity to vit D * Patients taking vitamin D supplements in the last 6 months.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Alopecia areata are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

alopecia areata

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Alopecia areata

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Rana Ehab

    RECRUITING

    Zagazig, 44519, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.